312 related articles for article (PubMed ID: 22444587)
1. Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships.
Bemporad F; Chiti F
Chem Biol; 2012 Mar; 19(3):315-27. PubMed ID: 22444587
[TBL] [Abstract][Full Text] [Related]
2. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity.
Fändrich M
J Mol Biol; 2012 Aug; 421(4-5):427-40. PubMed ID: 22248587
[TBL] [Abstract][Full Text] [Related]
3. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.
Glabe CG
Neurobiol Aging; 2006 Apr; 27(4):570-5. PubMed ID: 16481071
[TBL] [Abstract][Full Text] [Related]
4. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
[TBL] [Abstract][Full Text] [Related]
5. Structural properties and dynamic behavior of nonfibrillar oligomers formed by PrP(106-126).
Walsh P; Neudecker P; Sharpe S
J Am Chem Soc; 2010 Jun; 132(22):7684-95. PubMed ID: 20465257
[TBL] [Abstract][Full Text] [Related]
6. Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity.
Stefani M
Neuroscientist; 2007 Oct; 13(5):519-31. PubMed ID: 17901260
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of neurotoxic tau oligomers.
Lasagna-Reeves CA; Castillo-Carranza DL; Guerrero-Muoz MJ; Jackson GR; Kayed R
Biochemistry; 2010 Nov; 49(47):10039-41. PubMed ID: 21047142
[TBL] [Abstract][Full Text] [Related]
8. [Neurodegenerative conformational disease and its molecular bases].
Li WW; Cai DF; Ren HM
Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610
[TBL] [Abstract][Full Text] [Related]
9. Protein-misfolding diseases and chaperone-based therapeutic approaches.
Chaudhuri TK; Paul S
FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
[TBL] [Abstract][Full Text] [Related]
10. Glycosaminoglycans (GAGs) suppress the toxicity of HypF-N prefibrillar aggregates.
Saridaki T; Zampagni M; Mannini B; Evangelisti E; Taddei N; Cecchi C; Chiti F
J Mol Biol; 2012 Aug; 421(4-5):616-30. PubMed ID: 22326346
[TBL] [Abstract][Full Text] [Related]
11. Proteopathy: the next therapeutic frontier?
Walker LC; LeVine H
Curr Opin Investig Drugs; 2002 May; 3(5):782-7. PubMed ID: 12090553
[TBL] [Abstract][Full Text] [Related]
12. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
Gadad BS; Britton GB; Rao KS
J Alzheimers Dis; 2011; 24 Suppl 2():223-32. PubMed ID: 21460436
[TBL] [Abstract][Full Text] [Related]
13. Amyloid oligomer conformation in a group of natively folded proteins.
Yoshiike Y; Minai R; Matsuo Y; Chen YR; Kimura T; Takashima A
PLoS One; 2008 Sep; 3(9):e3235. PubMed ID: 18800165
[TBL] [Abstract][Full Text] [Related]
14. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit.
Guest WC; Silverman JM; Pokrishevsky E; O'Neill MA; Grad LI; Cashman NR
J Toxicol Environ Health A; 2011; 74(22-24):1433-59. PubMed ID: 22043906
[TBL] [Abstract][Full Text] [Related]
15. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.
Naeem A; Fazili NA
Cell Biochem Biophys; 2011 Nov; 61(2):237-50. PubMed ID: 21573992
[TBL] [Abstract][Full Text] [Related]
16. Amyloid peptides and proteins in review.
Harrison RS; Sharpe PC; Singh Y; Fairlie DP
Rev Physiol Biochem Pharmacol; 2007; 159():1-77. PubMed ID: 17846922
[TBL] [Abstract][Full Text] [Related]
17. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits.
Stefani M
Prog Neurobiol; 2012 Dec; 99(3):226-45. PubMed ID: 22450705
[TBL] [Abstract][Full Text] [Related]
18. Amino acid sequence determinants and molecular chaperones in amyloid fibril formation.
Nerelius C; Fitzen M; Johansson J
Biochem Biophys Res Commun; 2010 May; 396(1):2-6. PubMed ID: 20494101
[TBL] [Abstract][Full Text] [Related]
19. Oligomerization preceding amyloid fibril formation: a process in common to intrinsically disordered and globular proteins.
Zerovnik E
Network; 2011; 22(1-4):154-61. PubMed ID: 22149676
[TBL] [Abstract][Full Text] [Related]
20. Amyloid oligomers: dynamics and toxicity in the cytosol and nucleus.
Kitamura A; Kubota H
FEBS J; 2010 Mar; 277(6):1369-79. PubMed ID: 20148962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
